Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
Conclusions:
Elafin predicts poor outcome in breast and ovarian cancer patients delineates a subset of endocrine receptor positive breast cancer patients susceptible to recurrence whom could benefit from more aggressive intervention. Our in vitro results suggest that elafin arrests cell luminal breast cancer cells, perhaps suggesting a role in tumor dormancy.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Joseph CarusoCansu KarakasJing ZhangMin YiConstance AlbarracinAysegul SahinMelissa BondyJinsong LiuKelly HuntKhandan Keyomarsi Source Type: research
More News: Borderline Tumor | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Cystadenoma | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Epithelial Cancer | Ovarian Cancer | Ovaries | Study